Diaceutics PLC DXRX.L · Stock Open Diaceutics PLC in new tab
Diaceutics PLC Analysis (DXRX.L)
Is Diaceutics PLC a good investment? Diaceutics PLC (DXRX.L) is currently trading at 165.00 GBX. Market analysts have a consensus price target of 213.00 GBX. This suggests a potential upside from current levels.
Earnings Schedule: Diaceutics PLC is expected to release its next earnings report on Sept. 29, 2026. The market consensus estimate for Forward EPS is 0.04.
Investor FAQ
Does Diaceutics PLC pay a dividend?
No, it does not currently pay a dividend.
What asset class is Diaceutics PLC?
Diaceutics PLC is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be Sept. 29, 2026. The company currently has a trailing EPS of -0.02.
Company Profile
Diaceutics PLC, a diagnostic commercialization company, provides data, data analytics, and implementation services for pharma and biotech companies. The company offers DXRX, a diagnostic commercialization platform for precision medicine that integrates multiple pipelines of diagnostic testing data from a network of laboratories. It also provides DXRX data solutions, including DXRX Signal, that enables potential therapy eligibility for patients within hours of a diagnostic event, enabling teams to act while treatment decisions are still pending; DXRX Physician Mapping that examines physician testing behavior using patient level data to determine testing rates, methodology, and physician to lab relationship; DXRX Lab Mapping that offers insights into labs currently testing patients diagnosed with a specific disease or biomarker; and DXRX Disease Testing Rate Tracker, which delivers biomarker testing rate reports. In addition, the company offers scientific and advisory services. It operates in North America, the United Kingdom, Europe, Asia, and internationally. The company was incorporated in 2005 and is headquartered in Belfast, the United Kingdom.
Community Discussion